

**Unaudited Financial Results (Provisional) for the Quarter &
Nine months ended
31st December, 2003**

(Rs. in Lacs)					
Particulars	For the quarter ended		For the Nine Months ended		Year ended
	31-12-2003 (Unaudited)	31-12-2002 (Unaudited)	31-12-2003 (Unaudited)	31-12-2002 (Unaudited)	31-03-2003 (Audited)
Sales	10,661	10,227	17,277	19,432	28,386
Less : Excise Duty	330	332	883	1,192	1,471
Income from Operations	10,331	9,895	16,394	18,240	26,915
Other Income	58	337	234	743	294
Total Income	10,389	10,232	16,628	18,983	27,209
(Increase) / Decrease in Stocks	(1,301)	59	(3,087)	(4,455)	(797)
Consumption of Materials & Bought Outs	5,440	5,818	9,548	13,919	14,771
Manufacturing Expenses	608	493	1,323	950	1,283
Personnel Expenses	636	476	1,990	1,622	2,357
Others	1,300	1,035	3,663	2,914	4,082
Total Expenditure	6,683	7,881	13,437	14,950	21,696
Financial Expenses	96	318	331	898	1,187
Gross Profit after interest but before Depreciation & Tax	3,610	2,033	2,860	3,135	4,326
Depreciation	257	335	701	787	963
Operating Profit before tax & Extra-ordinary items	3,353	1,698	2,159	2,348	3,363
Provision for taxation	580	595	580	850	1,350
Deferred Tax Liabilities/ (Assets)	4	(75)	(22)	(68)	(129)
Net Profit / (Loss)	2,769	1,178	1,601	1,566	2,142
Paid-up Share Capital					
- Equity (Re. 1/- per share)	571	571	571	571	571
- 12% Preference Shares (Rs. 10/- per share)	535	535	535	535	535
Reserves & Surplus	-	-	-	-	9,481
E.P.S. (Rs.) (Basic & Diluted)	4.82	2.04	2.71	2.66	3.62
Aggregate of Non-Promoters' Shareholding					
- Number of shares	12,905,000	12,905,000	12,905,000	12,905,000	12,905,000
- Percentage of holding	22.61	22.61	22.61	22.61	22.61

Unaudited Segment wise Revenue, Results and Capital employed (Rs. in Lacs)

Particulars	For the Quarter ended		For Nine Months ended		Year ended
	31.12.03 (Unaudited)	31.12.02 (Unaudited)	31.12.03 (Unaudited)	31.12.02 (Unaudited)	31.03.03 (Audited)
Segment Revenue					
A. Vaccines	7,346	7,383	7,506	10,910	16,923
B. Formulations (net of excise duty)	3,034	2,714	9,029	7,890	10,105
C. Research & Development	6	-	70	31	115
Gross Sales / Income from Operations	10,386	10,097	16,605	18,831	27,143
Less : Inter Segment Revenue	-	-	-	-	-
Net Sales / Income from Operations	10,386	10,097	16,605	18,831	27,143
Segment Results					
A. Vaccines	3,731	1,979	3,331	3,428	5,145
B. Formulations	441	139	1,167	1,027	1,549
C. Research & Development	(279)	(178)	(771)	(580)	(833)
Total	3,893	1,940	3,727	3,875	5,861
Less : Interest & Financial Charges	96	318	331	897	1,187
Unallocated Overheads net of unallocated Income	444	(76)	1,237	630	1,310
Total Profit Before Tax	3,353	1,698	2,159	2,348	3,363
Capital Employed					
A. Vaccines	20,638	11,552	20,638	11,552	14,255
B. Formulations	7,671	7,715	7,671	7,715	7,633
C. Research & Development	1,619	1,560	1,619	1,560	1,748
Capital employed in Segments	29,928	20,827	29,928	20,827	23,636
Add : Unallocable Assets					
Less Liabilities (including investments)	(17,739)	(11,255)	(17,739)	(11,255)	(13,048)
Total Capital Employed	12,189	9,572	12,189	9,572	10,588

Notes :

1. **Segment Reporting** : Segments have been identified in accordance with the Accounting Standard on Segment Reporting (AS-17). Interest, borrowings and investments have been considered as unallocable items.
2. Deferred Tax Assets/Liabilities have been calculated in accordance with Accounting Standard AS 22 (Accounting for Taxes on Income) issued by the Institute of Chartered Accountants of India.
3. During the quarter, the Company had launched **ThankGod Relief Capsules, Anytime Cream & Isabgol Husk** (for treatment of piles), **Awayke MD** (anti-allergic), **Toff MD** (for cough & cold) and **Well-Beeing Tablets** (for Menstrual Pain) under Umbrella Brand name of **Best on Health** and **Ecovac-4** (a Combination Vaccine containing DTPw and Hepatitis B Antigen).
4. The previous period's figures have been regrouped/ rearranged/ reclassified wherever necessary.
5. Status of Investors' complaints [in nos.] during the quarter, pursuant to the clause 41 of the listing agreement: Opening [1]; Received [5]; Disposed [6]; Closing [0].
6. The above results were reviewed by the Audit Committee of the Board and taken on record by the Board of Directors at their meetings held on 29th January, 2004 and 30th January, 2004 respectively.

New Delhi
January 30, 2004

For and on behalf of the Board

Soshil Kumar Jain
Chairman

Panacea Biotec Ltd.

Regd. Office : Ambala-Chandigarh Highway, Lalru-140501, Punjab
Website : <http://www.panacea-biotec.com>